Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06114511 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06114511 · ClinicalTrials.gov record · last posted 2026-08-27

A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer

Name: A Study of BL-M07D1 in Patients With HER2-mutated, Locally Advanced or Metastatic Non-small-cell Lung Cancer — clinical trial record (NCT06114511)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusActive, Not Recruiting

PhasePhase 1/2

SponsorSichuan Baili Pharmaceutical Co., Ltd.

Started2024-04-24

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase Ib/II study is designed to evaluate the safety, tolerability, pharmacokinetics, and efficacy of injectable BL-M07D1 in patients with HER2-mutated, locally advanced or metastatic non-small cell lung cancer.

Protocol amendment history 4 changes detected by DataLookout

2026-08-28

Enrollment closed, study ongoing

2026-08-28

Enrollment reduced: 98 → 78 participants

2026-07-24

Primary completion pushed: 2026-04 → 2026-12

2026-07-24

Completion pushed: 2026-04 → 2027-12

Trial Details

NCT Number	NCT06114511
Lead Sponsor	Sichuan Baili Pharmaceutical Co., Ltd.
Conditions	Non-small Cell Lung Cancer
Enrollment	78 participants
Start Date	2024-04-24
Primary Completion	2026-12 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-27